Premium
Myeloproliferative disorder therapy: assessment and management of adverse events—a psychiatrist's perspective
Author(s) -
McDonald Graeme
Publication year - 2009
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.913
Subject(s) - perspective (graphical) , mood , medicine , psychiatry , adverse effect , intensive care medicine , psychotherapist , mood disorders , clinical psychology , psychology , anxiety , artificial intelligence , computer science
Chronic diseases such as the myeloproliferative disorders may mask a worsening emotional state in patients, which can be exacerbated by the addition of common treatments such as interferon‐ α . Management of mood disturbances is best considered from the first consultation, as the negative impact of impaired emotional well‐being on physiological outcomes is well established in literature. It is therefore important for physicians to be mindful of their patients' emotional well‐being from the point of diagnosis and throughout therapy, and aware of the tendency for physicians to focus on the primary illness. The advice of a psychiatrist may prove useful when discussing management strategies for patients with identifiable mood disturbances. Copyright © 2009 John Wiley & Sons, Ltd.